FY2024 EPS Estimates for Natera Boosted by Leerink Partnrs

Natera, Inc. (NASDAQ:NTRA) – Leerink Partnrs increased their FY2024 earnings estimates for shares of Natera in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn ($1.27) per share for the year, up from their prior forecast of ($1.61). The consensus estimate for Natera’s current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.19) EPS.

Several other research firms have also recently weighed in on NTRA. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Morgan Stanley upped their price target on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler lifted their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Finally, Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $162.94.

Natera Trading Down 0.1 %

Shares of NTRA stock opened at $171.82 on Thursday. Natera has a twelve month low of $62.96 and a twelve month high of $183.00. The stock’s fifty day simple moving average is $165.35 and its 200 day simple moving average is $135.41. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $22.68 billion, a P/E ratio of -97.63 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the business earned ($0.95) earnings per share. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NTRA. Blue Trust Inc. grew its holdings in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares during the last quarter. Quarry LP lifted its position in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. Versant Capital Management Inc boosted its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Covestor Ltd increased its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after purchasing an additional 106 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider John Fesko sold 669 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the transaction, the insider now owns 114,142 shares in the company, valued at approximately $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the completion of the sale, the insider now owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This represents a 1.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 224,133 shares of company stock worth $36,830,652. 7.60% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.